Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of beta 3-adrenergic receptor agonist in preparation of medicine for treating brain injury

A technology of epinephrine and therapeutic drugs, applied in the field of medicine, can solve the problem of lack of effective surgical or recognized drug treatment methods for cerebral hemorrhage, and achieve the effect of inhibiting focal brain inflammation and edema

Inactive Publication Date: 2021-03-09
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, in addition to craniotomy as a life-saving measure for critically ill patients, there is still a lack of effective surgical or recognized drug treatments for cerebral hemorrhage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of beta 3-adrenergic receptor agonist in preparation of medicine for treating brain injury
  • Application of beta 3-adrenergic receptor agonist in preparation of medicine for treating brain injury
  • Application of beta 3-adrenergic receptor agonist in preparation of medicine for treating brain injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1: detect the cell (Ly6C of cerebral hemorrhage model mouse low , HSCs) and protein (Cdc42) changes

[0072] 1. Experimental animals:

[0073] B6. Cg-Gt(ROSA)26S, Fgd5-CreERT2, α-catulin GFP , Adrb3- / - mice, 3-4 months old, male.

[0074] 2. Model establishment:

[0075] Fgd5-CreERT2 mice were crossed with B6.Cg-Gt(ROSA)26S mice to obtain Fgd5-CreER-tdTomato mice. All mutant mice were backcrossed to the B6 background for at least 12 generations.

[0076] After mice were anesthetized by intraperitoneal injection of ketamine / xylazine, the mouse head was placed in a stereotaxic apparatus. After disinfecting and exposing the skull, drill a hole on the right side of the skull. The hole diameter needs to be able to insert a 30g needle, and the coordinates are 2.3mm to the right and 0.5mm to the front. For the autologous blood model, non-heparinized blood was drawn from the mouse corneal vein after anesthesia. Blood was then injected using a microsyringe wi...

Embodiment 2

[0084] Example 2: Detection of changes in blood cells and brain damage in cerebral hemorrhage model mice after administration of mirabegron

[0085] 1. Experimental animals:

[0086] C57BL / 6 mice, 3-4 months old, male, were randomly divided into mirabegron administration group and control group.

[0087] 2. Model establishment:

[0088] After anesthetized by intraperitoneal injection of ketamine / xylazine, place the mouse head in a stereotaxic apparatus. After disinfecting and exposing the skull, drill a hole on the right side of the skull. The hole diameter needs to be able to insert a 30g needle, and the coordinates are 2.3mm to the right and 0.5mm to the front. For the autologous blood model, non-heparinized blood was drawn from the mouse corneal vein after anesthesia. Blood was then injected using a microsyringe with a 30 g needle. Insert the needle into the 3.7mm deep hole. After 15 minutes, 30 μL of autologous blood was injected into the brain parenchyma at a rate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and relates to application of a beta 3-adrenergic receptor agonist in preparation of a medicine for treating or preventing brain injury. Theresearch finds that the beta 3-adrenergic receptor agonist can increase Ly6Clow mononuclear cells and macrophages expressing alternative activation markers (CD206 and PD-L2) in the brain of a cerebralhemorrhage model mouse, and reduce neutrophil and lymphocyte which are infiltrated by brain tissues; and the beta 3-adrenergic receptor agonist promotes intramedullary hematopoiesis of the Ly6Clow mononuclear cells, promotes the Ly6Clow mononuclear cells and the macrophages to express IL-10, can effectively inhibit focal brain inflammation and edema after cerebral hemorrhage, and has important clinical application value for treating the brain injury after the cerebral hemorrhage. The invention further discloses a pharmaceutical composition. The pharmaceutical composition comprises the beta 3-adrenergic receptor agonist, and can be used as a medicine for treating the brain injury caused by the cerebral hemorrhage.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of β3-adrenergic receptor agonists in the preparation of medicines for the treatment or prevention of brain damage, in particular to the application of Mirabegron in the preparation of medicines for the treatment or prevention of brain damage. Background technique [0002] Intracranial hemorrhage (ICH) refers to hemorrhage caused by rupture of blood vessels in the non-traumatic brain parenchyma, accounting for 20% to 30% of all strokes, and the fatality rate in the acute phase is 30% to 40%. In my country, the incidence rate of cerebral hemorrhage is 60-80 / (100,000 people per year), and the prevalence rate is 112 / 100,000 people, which is much higher than that in Western countries and other Asian countries. It has been reported that the mortality rate 1 month after cerebral hemorrhage is 40%, and most of the survivors have sequelae such as movement disorders, cognit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/426A61K45/06A61P25/00A61P7/04A61P7/10
CPCA61K31/426A61K45/06A61P7/04A61P7/10A61P25/00
Inventor 施乡雨史凯斌刘强
Owner BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com